Vasculogenic mimicry in melanoma tissue : immunohistochemistry, cell growth & morphological assays, migration & invasion assays and protein expression analyses

This dataset supports a study investigating the role of vasculogenic mimicry in melanoma through both in vivo and in vitro approaches. Immunohistochemistry was used to evaluate the expression of VCAM1 and VEGF-A in tissue samples from eleven melanoma patients, revealing intratumoral expression patterns suggestive of a role in tumour growth and vasculogenic mimicry. Due to challenges with Western blotting in tissue samples, complementary in vitro studies were conducted using the B16-F10 (melanoma) cell line. Crystal violet assays, light and polarisation microscopy, and xCELLigence real-time analysis were employed to assess cell growth, morphology, and migration. Western blot analysis confirmed VEGFR-1 expression in melanoma cells, and VEGFR-1 blockade significantly reduced migration and invasion, reinforcing its role in vasculogenic mimicry.Sunitinib malate treatment induced morphological changes and decreased cell proliferation, supporting its apoptotic effects. Data were analysed using one-way ANOVA or nonparametric regression, with a sample size of nine for in vitro assays. The data from immunohistochemistry were analysed qualitatively in collaboration with an experienced pathologist. This dataset provides mechanistic insights and supports the therapeutic potential of targeting VEGFR-1 in melanoma.

本数据集支撑一项通过体内（in vivo）与体外（in vitro）实验手段，探究血管生成拟态（vasculogenic mimicry）在黑色素瘤中作用的研究课题。研究采用免疫组化（immunohistochemistry）技术，对11名黑色素瘤患者的组织样本中VCAM1与VEGF-A的表达水平进行检测，结果显示瘤内表达模式提示二者在肿瘤生长与血管生成拟态中发挥潜在作用。由于组织样本的蛋白质印迹（Western blotting）实验存在技术难点，研究团队借助B16-F10（黑色素瘤）细胞系开展了补充性体外实验。本次体外实验采用结晶紫染色实验（crystal violet assays）、明场与偏振光显微镜（light and polarisation microscopy）成像，以及xCELLigence实时细胞分析系统，分别评估细胞的生长状态、形态特征与迁移能力。蛋白质印迹分析证实了黑色素瘤细胞中血管内皮生长因子受体1（VEGFR-1）的表达，而阻断VEGFR-1可显著降低细胞迁移与侵袭能力，进一步验证了其在血管生成拟态中的关键作用。苹果酸舒尼替尼（sunitinib malate）处理可诱导细胞形态发生改变并降低细胞增殖活性，佐证了其促凋亡效应。体外实验的样本量为9，数据分析采用单因素方差分析（one-way ANOVA）或非参数回归方法。免疫组化数据则联合经验丰富的病理学家完成定性分析。本数据集提供了相关机制层面的科学见解，并支持靶向VEGFR-1在黑色素瘤治疗中的应用潜力。